Alzheimer's is a terrifying brain-destroying disease whose causes have proven very difficult to pin down. Physical chemists have shown precisely how a minor mutation results in unexpected changes in a very delicate chemical balance, creating build-up of the toxic by-products.
Ads by Google
Results of a study show that long-term nonsteroidal anti-inflammatory drug (NSAID) use was protective against Alzheimer disease.
Hispanic and black caregivers are more likely than other ethnic groups to misinterpret symptoms of Alzheimer's disease as normal signs of aging, according to a recent survey by the Alzheimer's Foundation of America, HealthDay/Washington Post reports. The survey found that 37% of black caregivers and 33% of Hispanic caregivers believed that the disease's symptoms were a normal part of aging, compared with 23% of caregivers from other racial or ethnic groups.
The survey also found that black and Hispanic caregivers were more likely to report that they knew little about Alzheimer's disease.
Alzheimer's patients treated with Medivation's investigational drug Dimebon showed improvement in the key aspects of cognitive function over a one-year period compared with placebo. The improvement occurred in not only memory and language, but also in more complex functions such as awareness of time and place, and praxis -- the process of getting an idea and initiating and completing a new motor task. These clinical results were generated during a pivotal trial of Dimebon in patients with mild-to-moderate Alzheimer's disease (AD).
Alzheimer's patients taking the investigational drug Dimebon showed significant improvement in their ability to perform daily tasks over a one-year period compared to placebo.
A study demonstrates natural antibodies contained in GAMMAGARD LIQUID, a plasma-derived antibody replacement therapy indicated for primary immunodeficiency disorders and being studied in Alzheimer's disease, binds directly to multiple aggregated, or clustered, forms of the beta-amyloid peptide molecule.
High cholesterol and bad habits like drinking alcohol and smoking cigarettes speeds the start Alzheimer's disease.
Scientists have recently obtained new data suggesting that recombinant butyrylcholinesterase (rBChE), a non-pegylated form of Protexia, may have neuroprotective benefits.
Alzheimer's patients don't show significant improvement of cognitive decline and neuropsychiatric problems when taking antipsychotic drugs.
Eli Lilly and Company starts a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the treatment of mild to moderate Alzheimer's disease. LY450139 is being tested to see if it can slow the progression associated with Alzheimer's disease by inhibiting gamma-secretase, an enzyme that can create a sticky protein called amyloid beta. Current Alzheimer's disease theory is that subtypes of amyloid beta clump together into plaques that eventually kill off brain cells.
Eli Lilly and Company has announced today the start of a Phase III clinical trial studying LY450139, an investigational gamma secretase inhibitor for the treatment of mild to moderate Alzheimer's disease.
Gamma secretase modulators have shown promise in Alzheimer's disease animal model efficacy studies.
Results from the third annual AFA ICAN: Investigating Caregivers' Attitudes and Needs Survey suggest that Alzheimer's disease care is a family affair.
Clinical results from a trial showed that behavioral symptoms were stabilized in patients with mild-to-moderate Alzheimer's disease over a one-year period.
Researchers believe that normal memory loss is hyper-activated in Alzheimer's disease (AD) and that this effect is key to the profound memory loss associated with the incurable neurodegenerative disorder.
The amyloid plaques found in the brains of Alzheimer's disease patients may form much more rapidly than previously expected. Using an advanced microscopic imaging technique to examine brain tissue in mouse models of the devastating neurological disorder, researchers from the MassGeneral Institute for Neurodegenerative Disease (MGH-MIND), working with colleagues from Washington University School of Medicine, find that plaques can develop in as little as a day and that Alzheimer's-associated neuronal changes appear soon afterwards. Their report will appear in the Feb. 7 issue of Nature.
Alzheimer's Disease publication designed to provide critical strategic insight for pharma and biotech companies with as take in the market for diagnostics and treatments in this disease area.
Researchers are launching an Alzheimer's screening clinical trial with Neuronetrix's innovative brain scanning system, called COGNISION. The study will involve brainwave assessments using a technology called event-related potentials (ERP's). The study is expected to validate the performance of the COGNISION system and to demonstrate the system's applicability in a primary care setting. Up to 100 Alzheimer sufferers and controls will participate over the next 6-12 months.
In a recent pre-clinical study an omega-3 fatty acid found in algae called docosahexaenoic acid, or DHA, was found to decrease an important risk factor for late-onset Alzheimer's disease. Conducted at the University of California, Los Angeles using a mouse model, a diabetic rat model, and cultured human cells, the study found that DHA increases the production of LR11, a protein vital to clearing the brain of the enzymes that make the beta amyloid plaques that are thought to cause Alzheimer's disease. The investigators used Martek's DHA from microalgae for a portion of the research.
Case Western Reserve University School of Medicine professor of neurology challenges conventional wisdom and assumptions of brain aging in new book 'The Myth of Alzheimer's'.
New study to create a large bank of genetic material, cell lines, and data from families with multiple members with late-onset Alzheimer's disease.
The TI Pharma project is a large-scale study into the brain material of Alzheimer's and Parkinson's patients, who gave permission to the Netherlands Brain Bank for their tissue to be used for scientific research.
Anavex Life Sciences announces promising developments with ANAVEX 1-41, the company's lead drug candidate for Alzheimer's disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress, which damages and destroys cells and is believed to be a primary cause of Alzheimer's disease. ANAVEX 1-41 also prevented the expression of caspase-3, an enzyme that plays a key role in programmed cell death and in the loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory.
Having hypertension, or high blood pressure, reduces blood flow in the brains of adults with Alzheimer's disease.